Document Detail

A phase I trial of the oral platinum analogue JM216 with concomitant radiotherapy in advanced malignancies of the chest.
MedLine Citation:
PMID:  11561689     Owner:  NLM     Status:  MEDLINE    
JM216 is an orally administered platinum analogue. We undertook this study to determine the maximally tolerated dose (MTD) of JM216 when administered with concomitant radiotherapy to the chest (200 cGy daily, 5 x/week) in patients with locoregionally advanced non-small cell lung (NSCLC) or esophageal cancer. Patients were excluded for inadequate bone marrow reserve, prior radiotherapy to the primary tumor or previous treatment with platinum drugs. A dose-limiting toxicity (DLT) was defined using the National Cancer Institute (NCI) Common Toxicity Criteria (CTC) and consisted of grade > or = 2 renal, hepatic, cardiac, or pulmonary toxicity or grade > or = 3 hematologic, neurological, or gastrointestinal toxicity. A total of 23 patients were registered; two never received treatment and are excluded from analyses. Six patients were treated at a dose of 30 mg/m2/day for 5 days with two grade 2 DLT's: cough (1 pt) and elevated trans-aminases (1 pt). Seven evaluable patients were treated at 60 mg/m2/day and seven experienced grade 3 or 4 toxicity, five related to myelosuppression. The dose was then reduced to 45 mg/m2/d. Eight patients were evaluable for toxicity, of which 5 experienced DLT: myelosuppression (3 pts), esophagitis (2 pts), dyspnea (1 pt), and elevated creatinine (1 pt). Fourteen patients were evaluable for efficacy, of which 6 had an objective response, including one complete response. The recommended phase II dose of JM216 with concurrent radiation therapy is 30 mg/m2/d for 5 days. The major DLT is myelosuppression with only limited increased toxicity within the field of radiation. This conceivably may limit the use of JM216 as a radiation sensitizer.
C M George; D J Haraf; A M Mauer; S A Krauss; P C Hoffman; C M Rudin; L Szeto; E E Vokes
Related Documents :
22028519 - A rare case of unusual gingival enlargement post radiotherapy.
1428729 - Phase i clinical trial and pharmacokinetic evaluation of doxorubicin carried by polyiso...
3163529 - A phase ii study of oral idarubicin (4-demethoxydaunorubicin) in advanced breast cancer.
3786819 - Weekly-dose doxorubicin (wda) in advanced breast cancer.
8422699 - Phase i clinical evaluation of [sp-4-3(r)]-[1,1-cyclobutanedicarboxylato(2-)](2-methyl-...
21741829 - Trastuzumab beyond progression: overall survival analysis of the gbg 26/big 3-05 phase ...
19866239 - Cks1b overexpression implicates clinical aggressiveness of hepatocellular carcinomas bu...
12494249 - Thermoradiotherapy for local control of chest wall invasion in patients with advanced n...
23500609 - Impact of beta blocker medication in patients with platinum sensitive recurrent ovarian...
Publication Detail:
Type:  Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Investigational new drugs     Volume:  19     ISSN:  0167-6997     ISO Abbreviation:  Invest New Drugs     Publication Date:  2001  
Date Detail:
Created Date:  2001-09-19     Completed Date:  2002-03-12     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  8309330     Medline TA:  Invest New Drugs     Country:  United States    
Other Details:
Languages:  eng     Pagination:  303-10     Citation Subset:  IM    
Section of Hematology/Oncology, University of Chicago, IL, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Oral
Antineoplastic Agents / administration & dosage*
Blood Cell Count
Carcinoma, Non-Small-Cell Lung / drug therapy,  radiotherapy
Combined Modality Therapy
Creatinine / analysis
Dose-Response Relationship, Drug
Esophageal Neoplasms / drug therapy*,  radiotherapy
Lung Neoplasms / drug therapy*,  radiotherapy*
Maximum Tolerated Dose
Middle Aged
Organoplatinum Compounds / administration & dosage*
Radiation Pneumonitis
Radiotherapy Dosage
Grant Support
Reg. No./Substance:
0/Antineoplastic Agents; 0/Organoplatinum Compounds; 129580-63-8/satraplatin; 60-27-5/Creatinine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Gene expression profiling of exposure to TZT-1027, a novel microtubule-interfering agent, in non-sma...
Next Document:  Evaluation of gemcitabine in patients with recurrent or metastatic squamous cell carcinoma of the he...